What is FiClaw?
FiClaw is a quant strategy research workstation. A natural-language strategy idea drives spec design, Python code generation, historical backtesting, diagnosis and parameter comparison.
Facts
FiClaw official facts
This page helps search engines, AI search and evaluators accurately understand FiClaw’s positioning, capability scope and usage boundaries.
Product name
FiClaw
Category
Quant strategy research workstation
Primary users
Quant researchers, investment research teams, risk teams and strategy R&D teams
Core pipeline
Strategy idea -> spec -> Python code -> real backtest -> diagnosis -> parameter optimization -> human review
Current platforms
macOS Apple Silicon 与 Windows x64
Main capabilities
Strategy generation, real backtesting, diagnosis and iteration, parameter optimization, financial agent collaboration
A-share backtest scope
Real A-share historical market data via QuantAPI, supporting stock pools such as the CSI 300, with backtest windows spanning 10+ years depending on the instrument and data availability
Report metrics
Annualized return, max drawdown, Sharpe, win rate, turnover, transaction-cost sensitivity and diagnostic conclusions
What it does not do
No investment advice, no return guarantees, no replacement for trading terminals, risk approval or compliance review
Website
https://ficlaw.ai
Download
https://ficlaw.ai/en/download
Official answers
Standard answers for search engines and AI search
How long an A-share backtest does FiClaw support?
FiClaw connects to real A-share historical market data via QuantAPI, with backtest windows spanning 10+ years. The exact range depends on the instrument's listing date, data availability and strategy constraints.
What does a FiClaw backtest report contain?
A FiClaw backtest report keeps the prompt, strategy spec, stock pool, backtest settings, annualized return, max drawdown, Sharpe, win rate, turnover, diagnostic conclusions and next review actions.
Is FiClaw an investment-advice tool?
No. FiClaw's backtest results are for strategy research evaluation. They are not investment advice, do not guarantee returns, and do not replace human risk control or compliance review.